← Kelly Casteel, MD

The Maintenance Era of Ovarian Cancer

An interactive, clinician-facing chronicle of the trials that built modern ovarian cancer care — from the platinum and platinum–taxane chemotherapy backbone through anti-angiogenic bevacizumab, the PARP-inhibitor maintenance revolution driven by BRCA/HRD status, and the arrival of the folate-receptor-α antibody–drug conjugate. Click any drug to trace its Phase 1→3→approval lineage; click a trial for arms, endpoints, results, and FDA/EMA milestones.

Data verified against ClinicalTrials.gov & primary literature · last reviewed Jul 2026

View

Drug class

Trial phase

Ph 1 Ph 2 Ph 3

Status

Approved Investigational Withdrawn / failed

Activity

Ongoing only

NCCN

In NCCN v4.2026 Category 1 only

Reference

Solid outline = approved Dashed outline = investigational Dashed rose = withdrawn / failed Pulsing dot = ongoing trial ✓badge = FDA / EMA approved NCCN category badge (1 / 2A / biomarker) Ambient curve = rising survival as approvals accrue

Scroll horizontally → · click a drug node to open its trial lineage

NCCN preferred regimens by line of therapy

Derived from NCCN Clinical Practice Guidelines in Oncology — Ovarian Cancer / Fallopian Tube Cancer / Primary Peritoneal Cancer, Version 4.2026

Preference tiers (Preferred / Other Recommended / Useful in certain circumstances) and Categories of Evidence (1, 2A) are summarised for reference and attributed to NCCN. This is not a reproduction of the guideline; consult the authoritative, current version at nccn.org. Click a drug chip to jump to that agent’s trial lineage. Biomarker-restricted options (BRCA/HRD, FRα) are noted inline.